Blueprint Medicines (NASDAQ:BPMC) reported its Q1 earnings results on Thursday, May 4, 2023 at 07:00 AM.
Here’s what investors need to know about the announcement.
Earnings
Blueprint Medicines beat estimated earnings by 19.48%, reporting an EPS of $-2.15 versus an estimate of $-2.67.
Revenue was up $556 thousand from the same period last year.
Past Earnings Performance
Last quarter the company missed on EPS by $0.0 which was followed by a 3.38% increase in the share price the next day.
Here’s a look at Blueprint Medicines’s past performance:
| Quarter | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 |
|---|---|---|---|---|
| EPS Estimate | -2.65 | -2.49 | -2.23 | -1.94 |
| EPS Actual | -2.65 | -2.23 | -2.68 | -1.79 |
| Revenue Estimate | 34.43M | 43.37M | 37.24M | 36.65M |
| Revenue Actual | 38.78M | 65.98M | 36.55M | 62.73M |
To track all earnings releases for Blueprint Medicines visit their earnings calendar here.
This article was generated by Benzinga’s automated content engine and reviewed by an editor.
